XML 64 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue and Contract Acquisition Costs (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes the Company’s disaggregated revenue:
Years Ended December 31,
(in millions)202320222021
U.S.$1,251.0 $884.8 $651.5 
International410.1 363.0 359.9 
Total Omnipod Products1,661.1 1,247.8 1,011.4 
Drug Delivery36.0 57.5 87.4 
Total revenue$1,697.1 $1,305.3 $1,098.8 
Schedules of Concentration of Risk
The percentages of total revenue for customers that represent 10% or more of total revenue was as follows:
Years Ended December 31,

202320222021
Distributor A28%19%*
Distributor B24%16%*
Distributor C19%17%12%
* Represents less than 10% of revenue for the period.
The percentages of total net accounts receivable trade for customers that represent 10% or more of total net accounts receivable trade were as follows:
As of December 31,

20232022
Distributor A35%34%
Distributor B25%23%
Distributor C18%11%
Schedule of Deferred Revenue
Deferred revenue related to unsatisfied performance obligations was included in the following consolidated balance sheet accounts in the amounts shown:
As of December 31,
(in millions)20232022
Accrued expenses and other current liabilities$15.4 $16.1 
Other liabilities1.9 1.6 
Total deferred revenue$17.3 $17.7 
Revenue recognized from amounts included in deferred revenue at the beginning of each respective period was as follows:
As of December 31,
(in millions)202320222021
Deferred revenue recognized$16.0 $2.1 $4.4 
Schedule of Contract Acquisition Costs
Contract acquisition costs, representing capitalized commission costs related to new customers, net of amortization, were included in the following consolidated balance sheet captions in the amounts shown:
As of December 31,
(in millions)20232022
Prepaid expenses and other current assets$16.6 $15.2 
Other assets32.0 31.3 
Total capitalized contract acquisition costs, net$48.6 $46.5